C-o- Group In R Patents (Class 514/622)
-
Publication number: 20120010178Abstract: Methods, compounds and compositions for promoting motor neuron survival and the treatment of a neurodegenerative disorders such as Spinal Muscular Atrophy (SMA) are described herein.Type: ApplicationFiled: October 21, 2009Publication date: January 12, 2012Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Lee Rubin, Amy Sinor, Nina Ruslanovna Makhortova, Yin Miranda Yang, Monica Hayhurst Bennett
-
Publication number: 20110319487Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.Type: ApplicationFiled: June 28, 2011Publication date: December 29, 2011Applicant: Laboratoires THEAInventor: Fabrice Mercier
-
Publication number: 20110313038Abstract: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ?2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 22, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Publication number: 20110311623Abstract: The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient having lower hardness than the coated active substance and another excipient having higher hardness and larger particle size than the active substance are used as means for protecting the coating layer from being destroyed.Type: ApplicationFiled: March 12, 2008Publication date: December 22, 2011Inventors: Mikyoung Hahn, Jin-Woo Choi, Dae-Hyeon Kim
-
Patent number: 8080541Abstract: The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.Type: GrantFiled: August 19, 2010Date of Patent: December 20, 2011Assignee: Hoffman-La Roche Inc.Inventors: Sabine Kolczewski, Emmanuel Pinard
-
Publication number: 20110301179Abstract: A compound (particularly useful for inhibiting cancer) according to formula I: or a pharmaceutically acceptable salt thereof, wherein: x is 0 or 1; R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl; R7 is H, alkyl, alkyl amino, aminoacyl, hydroxyacyl, heteroaryl, heterocycloalkyl, alkyl heteroaryl or alkyl heterocycloalkyl; R8 is H or alkyl; A is O or N; and Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, provided that if R7 is H then Ar is aryl substituted with alkyl amino.Type: ApplicationFiled: October 21, 2009Publication date: December 8, 2011Inventors: Xiangshu Xiao, Bingbing Li
-
Patent number: 8071575Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.Type: GrantFiled: February 22, 2008Date of Patent: December 6, 2011Assignee: University of Louisville Research FoundationInventors: William M. Pierce, Jr., K. Grant Taylor, Leonard C. Waite
-
Publication number: 20110294880Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.Type: ApplicationFiled: August 10, 2011Publication date: December 1, 2011Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yusuke SAKAI, Akira Ohtori
-
Publication number: 20110293549Abstract: Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by: wherein A and B are individually selected from a hydrogen, a hydroxyl group and a halogen, with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen and when one of A and B is a halogen, the other of A and B is a halogen or a hydrogen; wherein Z is, for example, an aryl moiety; and wherein X1 and X2 are, for example, individually selected from a hydrogen and an alkyl moiety, wherein R1 and R2 are individually selected from an oxo, a hydroxyl or an ester group; wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt.Type: ApplicationFiled: February 2, 2010Publication date: December 1, 2011Applicant: ATHENA COSMETICS, INC.Inventor: MICHAEL C. BRINKENHOFF
-
Publication number: 20110294893Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicant: ALLERGAN, INC.Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
-
Publication number: 20110288179Abstract: The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Inventors: Arie GUTMAN, Igor Rukhman, Boris Tishin, Lev Yudovich, Alexander Vilensky, Boris Pertsikov, Gennady Nisnevich
-
Publication number: 20110275577Abstract: The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.Type: ApplicationFiled: January 10, 2011Publication date: November 10, 2011Applicant: Moleculin, LLCInventors: Anna Priebe, Waldemar Priebe
-
Publication number: 20110275603Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Applicants: Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.Inventors: Meyyappan MUTHUPPALANIAPPAN, Prashant K. BHAVAR, Srikant VISWANADHA, Swaroop Kumar V.S. VAKKALANKA, Gayatri S. MERIKAPUDI
-
Publication number: 20110269834Abstract: Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).Type: ApplicationFiled: August 21, 2009Publication date: November 3, 2011Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, PURDUE RESEARCH FOUNDATIONInventors: Arun K. Ghosh, Jun Takayama, Andrew David Mesecar, Michael E. Johnson, Kiira M. Ratia, Rima Chaudhuri, Debbie C. Mulhearn
-
Patent number: 8039513Abstract: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.Type: GrantFiled: July 20, 2005Date of Patent: October 18, 2011Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Zhiyun Kang, Zuze Wu, Zhuangrong Sun, Zhongxiong Tang
-
Publication number: 20110250285Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: ApplicationFiled: June 3, 2011Publication date: October 13, 2011Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
-
Publication number: 20110237551Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory is activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicants: BASF Beauty Care Solutions France S.A.S., Universite Joseph Fourier-Grenoble 1Inventors: Sabrina Okombi, Delphine Rival, Ahcene Boumendjel, Anne-Marie Mariotte, Eric Perrier
-
Publication number: 20110230437Abstract: A composition comprising a compound of formula I CH3CH(OH)CC?O)NR1R2 (I) where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one agrochemical selected from Othe group consisting of Tri nexepac ethyl, Mandipropamid, Abamcctin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)-lactamide.Type: ApplicationFiled: August 12, 2008Publication date: September 22, 2011Applicant: SYNGENTA LIMITEDInventors: Gordon Alastair Bell, Clair Louise Harris, Ian David Tovey
-
Publication number: 20110224294Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-cancer, anti-diabetic, and anti-neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA), and human spinal muscular atrophy (SMA).Type: ApplicationFiled: May 24, 2011Publication date: September 15, 2011Applicant: NATUREWISE BIOTECH & MEDICALS CORPORATIONInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chia-Wei Lin, Jing-Shi Huang, Li-Ling Chi, Ai-Ling Chen, Chi-Yun Lee, Yu-Chen Huang
-
Publication number: 20110224260Abstract: The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetes and ischemia, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.Type: ApplicationFiled: May 24, 2011Publication date: September 15, 2011Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Yueh-Hsiung Kuo, Ming-Jai Su
-
Publication number: 20110224304Abstract: The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R4 and R5 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R6 and R7 are independently selected from the group consisting of hydrogen atom, fluorine atom, methyl, ethyl, hydroxy group, and others; and R8 and R9 are independently selected from the group consisting of hydrogen atom, C1-6 alkyl, and others, which is useful as an agent for treating or preventing various types of epilepsy including partial seizures and/or generalized seizures.Type: ApplicationFiled: November 13, 2009Publication date: September 15, 2011Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Seiji Iwama, Tomoyuki Tanaka, Nana Najima
-
Patent number: 8017655Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.Type: GrantFiled: December 19, 2008Date of Patent: September 13, 2011Assignee: Allergan, Inc.Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
-
Publication number: 20110212994Abstract: Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.Type: ApplicationFiled: June 28, 2010Publication date: September 1, 2011Inventors: BRIAN CLEM, SUCHETA TELANG, JOHN TRENT, JASON CHESNEY, POORAN CHAND, GILLES TAPOLSKY
-
Patent number: 8003699Abstract: Disclosed is an amide compound represented by the following formula (1). (1) (In the formula, X1 represents a fluorine atom or a methoxy group; X2 represents a hydrogen atom, a halogen atom, a C1-C4 alkyl group or the like; Z represents an oxygen atom or a sulfur atom; and A represents an A1-CR6R7R8 group, an A2-Cy1 group or an A3-Cy2 group, wherein A1 represents a CH2 group or the like, A2 represents a single bond, a CH2 group or the like, Cy1 represents a C3-C6 cycloalkyl group substituted with a C1-C6 alkoxy group or the like, Cy2 represents a C3-C6 cycloalkyl group which may be substituted with at least one halogen atom or the like, R6 and R7 independently represent a C1-C4 alkyl group, and R8 represents a halogen atom, a hydroxyl group or the like.) The amide compound has excellent plant disease controlling activity.Type: GrantFiled: April 25, 2008Date of Patent: August 23, 2011Assignee: Sumitomo Chemical Company, LimitedInventors: Takashi Komori, Mayumi Kubota, Yuichi Matsuzaki
-
Patent number: 7999136Abstract: Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. (1) (In the formula, substituents represented by A, Z, X1, X2 and X3 and the like are as defined in the description.Type: GrantFiled: April 25, 2008Date of Patent: August 16, 2011Assignee: Sumitomo Chemical Company, LimitedInventors: Takashi Komori, Mayumi Kubota, Yuichi Matsuzaki
-
Publication number: 20110197318Abstract: PROBLEM Provided is a seed treatment agent having excellent control effect on plant diseases and a method for protecting a plant from plant diseases. SOLUTION A seed treatment agent comprising, as an active ingredient, an ?-methoxyphenylacetic acid compound represented by formula (1).Type: ApplicationFiled: September 17, 2009Publication date: August 11, 2011Applicant: Sumitomo Chemical Company, LimitedInventors: Masanao Takaishi, Makoto Kurahashi
-
Publication number: 20110182966Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.Type: ApplicationFiled: January 21, 2011Publication date: July 28, 2011Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman
-
Publication number: 20110178042Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L1-L4 A, B, R1-R4 and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.Type: ApplicationFiled: September 1, 2009Publication date: July 21, 2011Applicant: Pfizer Inc.Inventors: Matthew F. Brown, Charles F. Donovan, Edmund L. Eilsworth, Denton W. Hoyer, Timothy A. Johnson, Manjinder S. Lall, Chris Lim-Berakis, Sean T. Murphy, Debra A. Sherry, Clarke B. Taylor, Joseph S. Warmus
-
Publication number: 20110172208Abstract: The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or the like; R4 is cyano, lower alkoxycarbonyl, carboxy or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.Type: ApplicationFiled: June 26, 2009Publication date: July 14, 2011Applicant: Kissei Pharmaceutical Co., Ltd.Inventors: Takehiro Ishikawa, Satoko Kobayashi, Hitoshi Inoue, Yasunori Ueno, Masako Yoshida, Nobuyuki Tanaka
-
Publication number: 20110172239Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: ApplicationFiled: July 16, 2010Publication date: July 14, 2011Inventors: Alan D. SNOW, Beth NGUYEN, Gerardo CASTILLO, Virginia SANDERS, Thomas LAKE, Lesley LARSEN, Rex T. WEAVERS, Stephen LORIMER, David LARSEN, David L. COFFEN, Charlotte COFFEN
-
Publication number: 20110172177Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.Type: ApplicationFiled: January 11, 2011Publication date: July 14, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. McCAULEY, Rudolf A. BAUMGARTNER
-
Publication number: 20110172311Abstract: Methods and compositions for treating human papillomavirus infections are described.Type: ApplicationFiled: March 28, 2011Publication date: July 14, 2011Inventors: Elliot J. Androphy, James D. Baleja
-
Patent number: 7973079Abstract: Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.Type: GrantFiled: September 15, 2008Date of Patent: July 5, 2011Assignee: Revision Therapeutics, Inc.Inventors: Nathan L. Mata, Kim B. Phan, Tam V. Bui, Mustapha Haddach
-
Patent number: 7968577Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g.Type: GrantFiled: October 31, 2007Date of Patent: June 28, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Bingwei Vera Yang, Lidia M. Doweyko, Wayne Vaccaro, Tram N. Huynh, David R. Tortolani, T. G. Murali Dhar
-
Publication number: 20110152376Abstract: The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.Type: ApplicationFiled: November 22, 2010Publication date: June 23, 2011Applicant: ALLERGAN, INC.Inventors: Gyorgy F. Ambrus, Kiomars Karami, Ke Wu
-
Publication number: 20110152226Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.Type: ApplicationFiled: September 15, 2010Publication date: June 23, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas S. Scanlan, Martin J. Kelly, Jian Qiu, Sandra Tobias, Oline K. Ronnekleiv
-
Publication number: 20110152291Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: March 1, 2011Publication date: June 23, 2011Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. AYDT, Remo Kranich, Anke S. Busemann
-
Publication number: 20110144043Abstract: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.Type: ApplicationFiled: December 11, 2009Publication date: June 16, 2011Applicant: Dana-Farber Cancer InstituteInventor: David A. Frank
-
Publication number: 20110144124Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.Type: ApplicationFiled: January 20, 2011Publication date: June 16, 2011Inventors: Alan D. Snow, Qubai Hu, Thomas Lake
-
Publication number: 20110136807Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.Type: ApplicationFiled: June 29, 2007Publication date: June 9, 2011Applicant: Kinex Pharmaceuticals, LLCInventor: David G. Hangauer, JR.
-
Publication number: 20110130448Abstract: The present invention relates to a compound of the formula: R-AR—O—Y—R? Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R?, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicyclic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group.Type: ApplicationFiled: December 7, 2010Publication date: June 2, 2011Applicant: Bezwada Biomedical LLCInventor: Rao S. Bezwada
-
Publication number: 20110124737Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: December 10, 2010Publication date: May 26, 2011Applicant: ALLERGAN, INC.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
-
Publication number: 20110124736Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.Type: ApplicationFiled: November 5, 2010Publication date: May 26, 2011Applicant: ALLERGAN, INC.Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara
-
Patent number: 7947743Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.Type: GrantFiled: June 1, 2005Date of Patent: May 24, 2011Assignee: Les Laboratories ServierInventors: Christian De Bodinat, Elisabeth Mocaer
-
Patent number: 7947740Abstract: The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.Type: GrantFiled: August 29, 2007Date of Patent: May 24, 2011Assignee: Finetech Pharmaceutical LtdInventors: Arie Gutman, Igor Rukhman, Boris Tishin, Lev Yudovich, Alexander Vilensky, Boris Pertsikov, Gennady Nisnevich
-
Publication number: 20110118349Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.Type: ApplicationFiled: November 19, 2010Publication date: May 19, 2011Applicant: NOVAGALI PHARMA S.A.Inventors: Jean-Sébastien GARRIGUE, Frédéric LALLEMAND, Philippe DAULL, Christophe BAUDOUIN
-
Publication number: 20110112198Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein emulsions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal.Type: ApplicationFiled: November 9, 2010Publication date: May 12, 2011Applicant: ALLERGAN, INC.Inventors: Anuradha V. Gore, Kevin S. Warner
-
Publication number: 20110112187Abstract: The present invention relates to the use of tranilast and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and neuroregeneration. The invention furthermore relates to the use of tranilast and derivatives thereof for the in vitro differentiation of neuronal stem cells and the use of such pre-treated cells for stem cell therapy von neurological conditions.Type: ApplicationFiled: August 15, 2008Publication date: May 12, 2011Inventors: Armin Schneider, Anja Moraru, Carola Krüger, Rice Laage, Claudia Pitzer
-
Publication number: 20110105489Abstract: A plant disease controlling composition comprising, as active ingredients, a compound represented by the formula (I), as well as at least one compound A selected from the group consisting of dimoxystrobin, trifloxystrobin, azoxystrobin, pyraclostrobin, a compound represented by the formula (II) and an agrochemically acceptable salt of the compound represented by the formula (II) : wherein, R1, Q, X, Y, Z, M and n are as defined in the description.Type: ApplicationFiled: March 24, 2009Publication date: May 5, 2011Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Masato Soma, Masanao Takaishi
-
Publication number: 20110104055Abstract: Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Inventors: Alan Snow, Manfred Weigele, Lesley Larsen, Beth Nguyen, Thomas Lake, Gerardo Castillo, Virginia Sanders, Rex T. Weavers, Stephen Lorimer, David Larsen, David L. Coffen, Charlotte Coffen